

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6470962

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
HONG KONG INNOGEN PHARMACEUTICAL TECHNOLOGY CO. LTD.	12/09/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	KUNMING INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD.
<b>Street Address:</b>	6TH FLOOR, NO.166 KEYI ROAD, HIGH TECH INDUSTRIAL DEVELOPMENT ZONE
<b>City:</b>	KUNMING
<b>State/Country:</b>	CHINA
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	8278420
<b>Patent Number:</b>	8658174
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(607)565-0060
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	352-871-8920
<b>Email:</b>	info@wandkip.com
<b>Correspondent Name:</b>	W&K IP
<b>Address Line 1:</b>	PO BOX 439
<b>Address Line 4:</b>	PAINTED POST, NEW YORK 14870
<b>ATTORNEY DOCKET NUMBER:</b>	SZNY US8278420
<b>NAME OF SUBMITTER:</b>	JIE YANG
<b>SIGNATURE:</b>	/JIE YANG/
<b>DATE SIGNED:</b>	12/28/2020
<b>Total Attachments: 4</b>	
source=ASSIGNMENT2#page1.tif	
source=ASSIGNMENT2#page2.tif	
source=ASSIGNMENT2#page3.tif	
source=ASSIGNMENT2#page4.tif	

**PATENT ASSIGNMENT**

HONG KONG INNOGEN PHARMACEUTICAL TECHNOLOGY CO. LTD. ("Assignor")

Whose office is located at

14 SCIENCE MUSEUM ROAD, UNIT 17,9/F, TOWER A, HONG KONG.

**And**

Kunming Innogen Pharmaceutical Technology Co., Ltd. ("Assignee").

Whose address is located at

6th Floor, No.166 Keyi Road, High tech Industrial Development Zone, Kunming City,  
Yunnan Province, China.

**WHEREAS**, Assignor, is the owner of that United States registered patent registration number identified as follows: US 8,278,420

*For and on behalf of*  
Hong Kong Innogen Pharmaceuti  
香港英諾醫藥

**AND**

.....  
*Authori*

**WHEREAS**, Assignee, wishes to acquire the entire rights, title, and interest in the patent.

**NOW**, the parties agree as follows:

**1. Assignment.**

Assignor does hereby irrevocably assign to Assignee all rights, title, and interest (including but not limited to, all registration rights with respect to the patent, all goodwill and all other rights), in and to the patent.

**2. Consideration.** In consideration for the assignment set forth in Section 1, Assignor shall pay Assignee the sum of USD1.00, payable on December 9, 2020 .

**3. Representations and Warranties.**

Assignor represents and warrants to Assignee:

- a. Assignor has the right, power and authority to enter into this Agreement;
- b. Assignor is the exclusive owner of all right, title and interest, including all intellectual property rights, in the patent;
- c. The patent is free of any liens, security interests, encumbrances or licenses;
- d. The patent does not infringe the rights of any person or entity;
- e. There are no claims, pending or threatened, with respect to Assignor's rights in the patent;
- f. This Agreement is valid, binding and enforceable in accordance with its terms; and



g. Assignor is not subject to any agreement, judgment or order inconsistent with the terms of this Agreement.

**4. Attorney's Fees.**

Should either party hereto, or any heir, personal representative, successor or assign of either party hereto, resort to litigation to enforce this Agreement, the party prevailing in such litigation shall be entitled, in addition to such other relief as may be granted, to recover its or their reasonable attorneys' fees and costs in such litigation from the party against whom enforcement was sought.

**5. Entire Agreement.**

This Agreement, contains the entire understanding and agreement between the parties hereto with respect, and comes into effect after signing.

Technology Co., Limited  
商有限公司

**6. Amendment.**

This Agreement may be amended only by a writing signed by both parties.

Signature(s)


**7. Agreement to Perform Necessary Acts.**

Assignee agrees to perform any further acts and execute and deliver any documents that may be reasonably necessary to carry out the provisions of this Agreement.

**8. Governing Law.**

This Agreement shall be construed in accordance with, and all actions arising hereunder shall be governed by the laws of United States.

For and On Behalf Of the <sup>For and on behalf of</sup> **ASSIGNOR HONG KONG INNOCEN PHARMACEUTICAL TECHNOLOGY CO. LTD.**  
香港銀諾醫藥技術有限公司



Authorized Signature(s)

By:

Title: Director

Date: December 9, 2020

For and On Behalf Of the **ASSIGNEE Kunming Innogen Pharmaceutical Technology Co., Ltd.**



By:

Title: Director

Date: December 9, 2020



**PATENT ASSIGNMENT**

HONG KONG INNOGEN PHARMACEUTICAL TECHNOLOGY CO. LTD. ("Assignor")

Whose office is located at

14 SCIENCE MUSEUM ROAD, UNIT 17,9/F, TOWER A, HONG KONG.

**And**

Kunming Innogen Pharmaceutical Technology Co., Ltd. ("Assignee").

Whose address is located at

6th Floor, No.166 Keyi Road, High tech Industrial Development Zone, Kunming City,  
Yunnan Province, China.

**WHEREAS**, Assignor, is the owner of that United States registered patent registration number identified as follows: US 8,658,174.

*For and on behalf of*  
Hong Kong Innogen Pharmaceutical  
香港銀諾醫藥技

**AND**

.....  
*Authorizes*

**WHEREAS**, Assignee, wishes to acquire the entire rights, title, and interest in the patent.

**NOW**, the parties agree as follows:

**1. Assignment.**

Assignor does hereby irrevocably assign to Assignee all rights, title, and interest (including but not limited to, all registration rights with respect to the patent, all goodwill and all other rights), in and to the patent.

**2. Consideration.** In consideration for the assignment set forth in Section 1, Assignor shall pay Assignee the sum of USD1.00, payable on December 9, 2020 .

**3. Representations and Warranties.**

Assignor represents and warrants to Assignee:

- a. Assignor has the right, power and authority to enter into this Agreement;
- b. Assignor is the exclusive owner of all right, title and interest, including all intellectual property rights, in the patent;
- c. The patent is free of any liens, security interests, encumbrances or licenses;
- d. The patent does not infringe the rights of any person or entity;
- e. There are no claims, pending or threatened, with respect to Assignor's rights in the patent;
- f. This Agreement is valid, binding and enforceable in accordance with its terms; and



g. Assignor is not subject to any agreement, judgment or order inconsistent with the terms of this Agreement.

**4. Attorney's Fees.**

Should either party hereto, or any heir, personal representative, successor or assign of either party hereto, resort to litigation to enforce this Agreement, the party prevailing in such litigation shall be entitled, in addition to such other relief as may be granted, to recover its or their reasonable attorneys' fees and costs in such litigation from the party against whom enforcement was sought.

**5. Entire Agreement.**

This Agreement, contains the entire understanding and agreement between the parties hereto with respect, and comes into effect after signing.

**6. Amendment.**

This Agreement may be amended only by a writing signed by both parties.

Technology Co., Limited  
有限公司

Signature(s)

**7. Agreement to Perform Necessary Acts.**

Assignee agrees to perform any further acts and execute and deliver any documents that may be reasonably necessary to carry out the provisions of this Agreement.

**8. Governing Law.**

This Agreement shall be construed in accordance with, and all actions arising hereunder shall be governed by the laws of United States.

For and On Behalf Of the **ASSIGNOR HONG KONG INNOGEN PHARMACEUTICAL TECHNOLOGY CO. LTD.**  
Hong Kong Innogen Pharmaceutical Technology Co., Limited  
香港銀諾醫藥技術有限公司




Authorized Signature(s)



By:

Title: Director

Date: December 9, 2020



For and On Behalf Of the **ASSIGNEE Kunming Innogen Pharmaceutical Technology Co., Ltd.**



By:

Title: Director

Date: December 9, 2020

**PATENT**